Abstract
Background Open access (OA) publishing represents an exciting opportunity to facilitate dissemination of scientific information to global audiences. However, OA publication is often associated with significant article processing charges (APCs) for authors, which may thus serve as a barrier to publication.
Methods We identified oncology journals using the SCImago Journal & Country Rank database. All journals with an OA publication option and APC data openly available were included. We searched journal websites and tabulated journal characteristics, including APC amount (USD), OA model (hybrid vs full), 2-year impact factor (IF), H-index, number of citable documents, modality/treatment specific (if applicable), and continent of origin. We generated a multiple regression model to identify journal characteristics independently associated with OA APC amount.
Results Of 367 oncology journals screened, 251 met final inclusion criteria. The median APC was 2957 USD (IQR 1958-3450). On univariable testing, journals with greater number of citable documents (p<0.001), higher IF (p < 0.001), higher H-index (p < 0.001), and those using the hybrid OA model (p < 0.001) or originating in Europe/North America (p < 0.001) tended to have higher APCs. In our multivariable model, number of citable documents, IF, OA publishing model, and region persisted as significant predictors of processing charges.
Conclusions OA publication costs are greater in oncology journals that publish more citable articles, utilize the hybrid OA model, have higher IF, and are based in North America or Europe. These findings may inform targeted action to help the oncology community fully appreciate the benefits of open science.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NA
Clinical Protocols
NA
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was exempt from IRB approval.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Footnotes
Funding: This work is supported by core resources from the NIH/NCI Cancer Center Support Grant (CCSG) Radiation Oncology and Cancer Imaging Program (P30CA016672). Dr. Fuller received/receives funding and salary support during the period of study execution unrelated to this work from: National Institutes of Health (NIH) and National Science Foundation (NSF). Dr. Fuller receives grant and infrastructure support from MD Anderson Cancer Center via: the Charles and Daneen Stiefel Center for Head and Neck Cancer Oropharyngeal Cancer Research Program; the Program in Image-guided Cancer Therapy; and the NIH/NCI Cancer Center Support Grant (CCSG) Radiation Oncology and Cancer Imaging Program (P30CA016672-44). Dr. Fuller has received direct industry grant/in-kind support, honoraria, and travel funding from Elekta AB unrelated to this project. Dr. Fuller has received travel, speaker honoraria and/or registration fee waiver unrelated to this project from: The American Association for Physicists in Medicine; the University of Alabama-Birmingham; The American Society for Clinical Oncology; The Royal Australian and New Zealand College of Radiologists
Conflicts of Interest: Dr. Fuller serves as an Associate Editor for an ASCO-affiliated journal, receives honoraria for this role from ASCO.
Prior publication: These data were presented at the 2021 ASCO Annual Meeting.
Data Availability
Data will be available upon request to the corresponding author.
NA